Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for inhibiting ovarian carcinoma cells

A technology of ovarian cancer cells and composition, applied in the field of biomedicine, can solve problems such as large toxic and side effects

Inactive Publication Date: 2019-03-22
ZUNYI MEDICAL UNIVERSITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its toxic and side effects are also relatively large, such as renal toxicity, bone marrow suppression, neurotoxicity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for inhibiting ovarian carcinoma cells
  • Medicine composition for inhibiting ovarian carcinoma cells
  • Medicine composition for inhibiting ovarian carcinoma cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] The present invention will be further described below in conjunction with the examples, but the present invention is not limited to the following examples, it can be foreseen that those skilled in the art may produce various changes in the implementation under the condition of combining the prior art.

[0021] A pharmaceutical composition for inhibiting ovarian cancer cells, the composition is composed of 200ng / mL brefeldin A (BFA) and 4.0-4.5 μg / mL cisplatin (CDDP).

[0022] The combination of brefeldin A (BFA) and cisplatin (CDDP) can inhibit the growth and proliferation of ovarian cancer cells.

[0023] The combination of brefeldin A (BFA) and cisplatin (CDDP) promotes apoptosis of ovarian cancer cells.

[0024] The combination of brefeldin A (BFA) and cisplatin (CDDP) affects the expression of ovarian cancer cell apoptosis-related proteins.

[0025] The combination of brefeldin A (BFA) and cisplatin (CDDP) affects the expression of genes related to apoptosis of ova...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine composition for inhibiting ovarian carcinoma cells, and belongs to the technical field of the biological medicine. The composition is formed by combining 200ng / mL ofbrefeldin A (BFA) and 4.0-5.0microgram / mL of cisplatin (CDDP). The medicine composition can obviously inhibit the growth proliferation of the ovarian carcinoma cells and accelerate the apoptosis of the ovarian carcinoma cells, has a function of adjusting genes and protein related to the apoptosis of the ovarian carcinoma cells, is obvious superior to the individual medication, and has the effectof synergistically resisting the ovarian carcinoma cells. The medicine composition can be used as a target medicine composition for regulating and controlling the apoptosis pathway of the ovarian carcinoma cells, thereby providing a new comprehensive treatment strategy for the ovarian carcinoma clinically.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a pharmaceutical composition for inhibiting ovarian cancer cells. Background technique [0002] Cancer is a major disease that seriously threatens human survival and social development. Among them, ovarian cancer (ovarian carcinoma) is one of the three most common malignant tumors in women, and its incidence rate ranks third, after breast cancer and cervical cancer. However, because the ovary is located in the deep part of the pelvic cavity, early lesions are not easy to be found. Once symptoms appear, most of them are late. Therefore, its mortality rate ranks first in gynecological tumors. [0003] The current clinical treatment of ovarian cancer is a combination of surgery and chemotherapy. Chemotherapy can be used alone in the palliative treatment of advanced cancer, or as a part of comprehensive treatment, combined with surgery, radiotherapy, etc. Chemotherapy can preve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K33/24A61P35/00
CPCA61K31/365A61K33/24A61P35/00A61K2300/00
Inventor 耿娜娜郑翔吴明松李学英张志敏杨蕾
Owner ZUNYI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com